Tests a care program linking cancer and primary care teams for survivors
Tests a care program for adults with cancer and long-term health conditions.
Key facts
- Who runs it
- Rutgers, The State University of New Jersey
- Where
- New Brunswick, United StatesSee the site
- Trial code
- Registry title
- Advancing Care Coordination Between Cancer and Primary Care Teams for Complex Cancer Survivors
- Status
- Enrolling by invitation
- People taking part
- 266 people, planned
- Started
- 24 Apr 2026
- Expected to end
- 30 Apr 2029
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- PC2: Primary Care Connect
- Record updated
- 10 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with early-stage breast, prostate, bladder or endometrial cancer who also have high blood pressure, high cholesterol or type II diabetes needing medicine, and who see a primary care provider.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Stage I-III breast, prostate, urinary bladder or endometrial cancer, diagnosed in the past 6 months. People who later develop metastatic disease during the 18-month trial can stay in.
- Earlier treatment
- Being treated for cancer with the aim of removing all of the disease, at the Rutgers Cancer Institute of New Jersey. First visit at the cancer center within the last 3 months.
Main reasons for not taking part
- Heart attack or stroke within the previous 1 year
- Heart failure with an ejection fraction <30%
- Stage IV-V chronic kidney disease (eGFR <30)
- Does not speak English or Spanish
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- diagnosed with any of the following cancers [Stage I-III]: breast, prostate, urinary bladder, and endometrial in the past 6 months
- being treated for cancer with curative intent
- had initial patient visit at the cancer center in the last 3 months
- are being treated for cancer with curative intent at the Rutgers Cancer Institute of New Jersey
- have ≥1 CVD risk factor (hypertension, hyperlipidemia or type II diabetes) prior to cancer diagnosis that requires medication management
- currently receiving care from a primary care provider
- Speak English or Spanish
Who cannot take part
- had myocardial infarction or stroke within the previous 1 year
- or do not speak English or Spanish. Patients whose cancer progresses to metastatic disease during the course of the 18-month trial will be allowed to continue to participate unless they voluntarily withdraw
- have heart failure with an ejection fraction <30%; (3) have stage IV-V chronic kidney disease (eGFR <30)
Where in United States
- Rutgers Cancer InstituteNew Brunswick, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
The purpose of this randomized clinical trial is to learn if 'complex' cancer patients who receive care guided by a health system intervention, Primary Care Connect (PC2) have their risks of cardiovascular disease (CVD) managed better than those who receive usual care. This study focuses on "complex" cancer survivors who have higher CVD risk when diagnosed with cancer because they also have had a diagnosis of 1 or more chronic conditions (e.g., hypertension, diabetes, and/or hyperlipidemia) requiring medication management. This study also aims to learn about the ease of implementing the health system intervention from the perspectives of cancer teams, primary care teams, and complex cancer patients.
Read full original descriptionShow less
The main questions the study aims to answer are:
* Do patients enrolled in the PC2 arm remain connected to their primary care teams during active cancer treatment for chronic disease management compared to patients in usual care? * Do patients enrolled in the PC2 arm have better management of their chronic conditions during active cancer treatment compared to patients in usual care? * How do the care team and patients experience this change in care delivery related to their work and care experiences?
This study will compare complex cancer survivors who receive care according to the PC2 intervention to usual care to see if PC2 works to improve cardiovascular risk management.
Participants will:
* receive educational materials about the study upon enrollment * complete on-line or written surveys at 4 times * Visit the clinic for check ups and test related to the study 4 times
The 2 groups in the trial
- Usual CareNo study treatment, for comparison
Patients in this arm will not receive the intervention.
- Primary Care Connect (PC2)Treatment being tested
Patients enrolled in this arm will be provided print and video educational materials about the importance of shared care to manage existing and prevent exacerbations in chronic disease management. Additionally, their cancer care team will provide a brief protocolized communication to their primary care team that explain how their initial treatment may impact chronic disease management, clarifying the primary care role during acute treatment, and providing contact information for cancer team. Primary care providers of patients enrolled in this arm will receive an outreach packet that includes information provided in print and short video to explain the rationale of the intervention and the materials provided by the cancer care team.
Treatment: PC2: Primary Care Connect
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- ACCESS-PC: Advancing Care Coordination to Enhance Shared Care for Complex Cancer Survivors in Primary Care.
- Plain-language title
- Tests a care program linking cancer and primary care teams for survivorsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Record updated
- 10 July 2026